Ibrutinib launched for treatment of mantle cell lymphoma and chronic lymphocytic leukaemia
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been launched in the UK for the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia.…
Published: 26 November 2014